| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
* Department of Physiology and Pennsylvania Muscle Institute, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA;
Department of Experimental Medicine, Glostrup Hospital, Glostrup, Denmark; and;
Cardiovascular and Metabolic Disease Department, Wyeth Research, Cambridge, Massachusetts, USA
1Correspondence: Department of Physiology and Pennsylvania Muscle Institute, A-601 Richards Building, University of Pennsylvania School of Medicine, 3700 Hamilton Walk, Philadelphia, PA 19104-6085, USA. E-mail: tsk{at}mail.med.upenn.edu
Mutations in myostatin (GDF8) cause marked increases in muscle mass, suggesting that this transforming growth factor-ß (TGF-ß) superfamily member negatively regulates muscle growth. Myostatin blockade therefore offers a strategy for reversing muscle wasting in Duchenne’s muscular dystrophy (DMD) without resorting to genetic manipulation. Here, we demonstrate that pharmacological blockade using a myostatin propeptide stabilized by fusion to IgG-Fc improved pathophysiology of the mdx mouse model of DMD. Functional benefits evidenced by specific force improvement, exceeded those reported previously using myostatin antibody-mediated blockade. More importantly, use of a propeptide blockade strategy obviates possibilities of anti-idiotypic responses that could potentially limit the effectiveness of antibody-mediated myostatin blockade strategies over time. This study provides a novel pharmacological strategy for treatment of diseases associated with muscle wasting such as DMD and since it uses an endogenous inhibitor of myostatin should help circumvent technical hurdles and toxicity associated with conventional gene or cell based therapies.
Key Words: DMD • dystroglycan complex • neuromuscular disease • dystrophin • extracellular matrix
This article has been cited by other articles:
|
|
 |
|
  R. Xu, S. DeVries, M. Camboni, and P. T. Martin Overexpression of Galgt2 Reduces Dystrophic Pathology in the Skeletal Muscles of Alpha Sarcoglycan-Deficient Mice Am. J. Pathol., July 1, 2009; 175(1): 235 - 247. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. L. Walton, Y. Makanji, M. C. Wilce, K. L. Chan, D. M. Robertson, and C. A. Harrison A Common Biosynthetic Pathway Governs the Dimerization and Secretion of Inhibin and Related Transforming Growth Factor {beta} (TGF{beta}) Ligands J. Biol. Chem., April 3, 2009; 284(14): 9311 - 9320. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. F. Rose Jr, V. B. Mattis, H. Rindt, and C. L. Lorson Delivery of recombinant follistatin lessens disease severity in a mouse model of spinal muscular atrophy Hum. Mol. Genet., March 15, 2009; 18(6): 997 - 1005. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. T. Martin, R. Xu, L. R. Rodino-Klapac, E. Oglesbay, M. Camboni, C. L. Montgomery, K. Shontz, L. G. Chicoine, K. R. Clark, Z. Sahenk, et al. Overexpression of Galgt2 in skeletal muscle prevents injury resulting from eccentric contractions in both mdx and wild-type mice Am J Physiol Cell Physiol, March 1, 2009; 296(3): C476 - C488. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Blaauw, C. Mammucari, L. Toniolo, L. Agatea, R. Abraham, M. Sandri, C. Reggiani, and S. Schiaffino Akt activation prevents the force drop induced by eccentric contractions in dystrophin-deficient skeletal muscle Hum. Mol. Genet., December 1, 2008; 17(23): 3686 - 3696. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. A. Souza, X. Chen, Y. Guo, P. Sava, J. Zhang, J. J. Hill, P. J. Yaworsky, and Y. Qiu Proteomic Identification and Functional Validation of Activins and Bone Morphogenetic Protein 11 as Candidate Novel Muscle Mass Regulators Mol. Endocrinol., December 1, 2008; 22(12): 2689 - 2702. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. D. Rodgers and D. K. Garikipati Clinical, Agricultural, and Evolutionary Biology of Myostatin: A Comparative Review Endocr. Rev., August 1, 2008; 29(5): 513 - 534. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Nakatani, Y. Takehara, H. Sugino, M. Matsumoto, O. Hashimoto, Y. Hasegawa, T. Murakami, A. Uezumi, S. Takeda, S. Noji, et al. Transgenic expression of a myostatin inhibitor derived from follistatin increases skeletal muscle mass and ameliorates dystrophic pathology in mdx mice FASEB J, February 1, 2008; 22(2): 477 - 487. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. L. Mendias, K. I. Bakhurin, and J. A. Faulkner Tendons of myostatin-deficient mice are small, brittle, and hypocellular PNAS, January 8, 2008; 105(1): 388 - 393. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Xu, K. Chandrasekharan, J. H. Yoon, M. Camboni, and P. T. Martin Overexpression of the Cytotoxic T Cell (CT) Carbohydrate Inhibits Muscular Dystrophy in the dyW Mouse Model of Congenital Muscular Dystrophy 1A Am. J. Pathol., July 1, 2007; 171(1): 181 - 199. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Welle, K. Bhatt, C. A. Pinkert, R. Tawil, and C. A. Thornton Muscle growth after postdevelopmental myostatin gene knockout Am J Physiol Endocrinol Metab, April 1, 2007; 292(4): E985 - E991. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Amthor, R. Macharia, R. Navarrete, M. Schuelke, S. C. Brown, A. Otto, T. Voit, F. Muntoni, G. Vrbova, T. Partridge, et al. Lack of myostatin results in excessive muscle growth but impaired force generation PNAS, February 6, 2007; 104(6): 1835 - 1840. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. D. Rodgers, E. H. Roalson, G. M. Weber, S. B. Roberts, and F. W. Goetz A proposed nomenclature consensus for the myostatin gene family Am J Physiol Endocrinol Metab, February 1, 2007; 292(2): E371 - E372. [Full Text] [PDF]
|
|
|
|
 |
|
 C. L. Mendias, J. E. Marcin, D. R. Calerdon, and J. A. Faulkner Contractile properties of EDL and soleus muscles of myostatin-deficient mice J Appl Physiol, September 1, 2006; 101(3): 898 - 905. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. A. Parsons, D. P. Millay, M. A. Sargent, E. M. McNally, and J. D. Molkentin Age-Dependent Effect of Myostatin Blockade on Disease Severity in a Murine Model of Limb-Girdle Muscular Dystrophy Am. J. Pathol., June 1, 2006; 168(6): 1975 - 1985. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
